The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

被引：156

作者：

Aguiar, Pedro N., Jr. ^{[1
]}

Santoro, Ilka Lopes ^{[1
]}

Tadokoro, Hakaru ^{[1
]}

Lopes, Gilberto de Lima ^{[2
,3
]}

Filardi, Bruno Andraus ^{[1
]}

Oliveira, Pedro ^{[4
]}

Mountzios, Giannis ^{[5
]}

de Mello, Ramon Andrade ^{[6
,7
]}

机构：

[1] Univ Fed Sao Paulo, Div Med Oncol, Sao Paulo, Brazil

[2] Oncoclin Brasil Grp, Sao Paulo, Brazil

[3] Johns Hopkins Univ, Dept Med Oncol, Singapore, Singapore

[4] Univ Porto, Abel Salazar Biomed Inst, Dept Populat Studies, Rua Campo Alegre 823, P-4100 Oporto, Portugal

[5] Univ Athens, Sch Med, Dept Med Oncol, GR-11527 Athens, Greece

[6] Univ Algarve, Dept Biomed Sci & Med, Faro, Portugal

[7] Univ Porto, Fac Med, Rua Campo Alegre 823, P-4100 Oporto, Portugal

来源：

IMMUNOTHERAPY | 2016年 / 8卷 / 04期

关键词：

anti-PDL1; clinical trials; lung cancer; meta-analysis; nivolumab; non-small-lung cancer; PD1; pembrolizumab; RANDOMIZED PHASE-III; DEATH-LIGAND; MAINTENANCE BEVACIZUMAB; 1ST-LINE TREATMENT; CLINICAL ACTIVITY; SAFETY; NIVOLUMAB; ANTIBODY; IMMUNOTHERAPY; CHEMOTHERAPY;

D O I：

10.2217/imt-2015-0002

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

Background: Tumor programmed death ligand one (PD-L1) expression has been studied in several trials in non-small-cell lung cancer. Methods: We assessed the potential role of PD-L1 expression according to Cochrane Collaboration's Guidelines. Results: 13 studies with 1979 patients were included. Among 915 PD-L1 negative patients this rate was 13% (RR 2.08; 95% CI: 1.49-2.91; p < 0.01). The response rate has increased concurrent to the PD-L1 expression (Pearson's correlation, r = 0.43). PD-L1 expression was also related to better 24-weeks progression-free rate (RR 0.79; 95% CI: 0.71-0.89) and a trend toward better 1-year overall survival rate (RR 0.96; 95% CI: 0.87-1.06). Conclusion: Taking this data in account, PD-L1 overexpression could not be currently considered a robust biomarker to tailor the immune checkpoint inhibitors treatment.

引用

页码：479 / 488

页数：10

共 37 条

[1]

[Anonymous], WHO GLOBOCAN 2012 ES

[2]

[Anonymous], ASCO ANN M S

[3]

[Anonymous], ASCO ANN M S

[4]

[Anonymous], COCHRANE HDB SYSTEMA

[5]

[Anonymous], ASCO ANN M S

[6]

[Anonymous], J CLIN ONCOL S

[7]

[Anonymous], ASCO ANN M S

[8]

[Anonymous], ASCO ANN M 2015 CHIC

[9]

[Anonymous], ASCO ANN M S

[10]

[Anonymous], J CLIN ONCOL

← 1 2 3 4 →